Olaparib: A promising PARP inhibitor in ovarian cancer therapy

Archives of Gynecology and Obstetrics

Volumn 288, Issue 2, 2013, Pages 367-374

  Chen, Ying ^a,b   Zhang, Lei ^a,b   Hao, Quan ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

Cancer; Clinical trial; Olaparib; PARP1 inhibitor

Indexed keywords

AGO 14699; AGO 4699; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BMN 673; BSI 401; CEP 9722; CISPLATIN; DACARBAZINE; DOXORUBICIN; GEMCITABINE; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG; VELIPARIB;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER RISK; CONCENTRATION RESPONSE; CYTOREDUCTIVE SURGERY; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; URINARY TRACT INFECTION; VOMITING;

ANTINEOPLASTIC AGENTS; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84880811116     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-013-2856-2     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90
2. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR (2009) Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 114(1):26-31
3. Chambon P, Weill JD, Mandel P (1963) Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 11:39-43
4. Langelier MF, Servent KM, Rogers EE, Pascal JM (2008) A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme activation. J Biol Chem 283(7):4105-4114
5. Tao Z, Gao P, Hoffman DW, Liu HW (2008) Domain C of human poly(ADP-ribose) polymerase-1 is important for enzyme activity and contains a novel zinc-ribbon motif. Biochemistry 47(21):5804-5813
6. Hassa PO, Haenni SS, Elser M, Hottiger MO (2006) Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going? Microbiol Mol Biol Rev 70(3):789-829
7. de Murcia G, Schreiber V, Molinete M, Saulier B, Poch O, Masson M, Niedergang C (1994) Ménissier de Murcia J. Structure and function of poly(ADP-ribose) polymerase. Mol Cell Biochem 138(1-2):15-24
8. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10(4):293-301
9. Clark JB, Ferris GM, Pinder S (1971) Inhibition of nuclear NAD nucleosidase and poly ADP-ribose polymerase activity from rat liver by nicotinamide and 5′-methyl nicotinamide. Biochim Biophys Acta 238(1):82-85
10. Durkacz BW, Omidiji O, Gray DA, Shall S (1980) (ADP-ribose)n participates in DNA excision repair. Nature 283(5747):593-596
11. Weil MK, Chen AP (2011) PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer 35(1):7-50
12. Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A et al (2008) 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H- phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 51(20):6581-6591
13. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123-134
14. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G et al (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366(15):1382-1392
15. Kaye SB, Lubinski J, Matulonis U et al (2012) Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30(4):372-379
16. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K et al (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12(9):852-861
17. Yamamoto N, Nokihara H, Yamada Y et al (2012) A phase I, dose-finding and pharmacokinetic study of Olaparib (AZD2281) in Japanese patients with advanced solid tumours. Cancer Sci 103(3):504-509
18. Audeh MW, Carmichael J, Penson RT et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376(9737):245-251
19. Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26(22):3785-3790
20. Underhill C, Toulmonde M, Bonnefoi H (2011) A review of PARP inhibitors: from bench to bedside. Ann Oncol 22(2):268-279
21. Fong PC, Yap TA, Boss DS et al (2010) Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28:2512-2519
22. Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14):3312-3322
23. Adams SF, Marsh EB, Elmasri W et al (2011) A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecol Oncol 123(3):486-491
24. Marchetti C, Imperiale L, Gasparri ML, Palaia I, Pignata S, Boni T, Bellati F (2012) Benedetti Panici P. Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opin Investig Drugs 21(10):1575-1584
25. Palma JP, Rodriguez LE, Bontcheva-Diaz VD et al (2008) The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res 28(5A):2625-2635
26. Donawho CK, Luo Y, Luo Y et al (2007) ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumour models. Clin Cancer Res 13(9):2728-2737
27. Carden CP, Yap TA, Kaye SB (2010) PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. Curr Opin Oncol 22(5):473-480
28. Samol J, Ranson M, Scott E et al (2011) Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, Olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumours: a phase I study. Invest New Drugs 30(4):1493-1500
29. Khan OA, Gore M, Lorigan P et al (2011) A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer 104:750-755
30. Dent RA, Lindeman GJ, Clemons M et al (2011) Safety and efficacy of the oral PARP inhibitor Olaparib (AZD2281) in combination with paclitaxel for the first or second-line treatment of patients with metastatic triple-negative breast cancer: results from the safety cohort of a phase I/II multicenter trial. J Clin Oncol 28(15S):1018 (abstract)
31. Rajan A, Carter CA, Kelly RJ et al (2012) A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumours. Clin Cancer Res 18(8):2344-2351
32. Dean E, Middleton MR, Pwint T et al (2012) Phase I study to assess the safety and tolerability of Olaparib in combination with Bevacizumab in patients with advanced solid tumours. Br J Cancer 106(3):468-474
33. Chan N, Bristow RG (2010) Contextual synthetic lethality and/or loss of heterozygosity: tumour hypoxia and modification of DNA repair. Clin Cancer Res 16:4553-4560